vs
Ponce Financial Group, Inc.（PDLB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Ponce Financial Group, Inc.的季度营收约是REGENXBIO Inc.的1.0倍（$31.4M vs $30.3M），Ponce Financial Group, Inc.净利率更高（36.3% vs -221.3%，领先257.6%），REGENXBIO Inc.同比增速更快（43.0% vs 37.6%），Ponce Financial Group, Inc.自由现金流更多（$54.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 23.7%）
庞塞金融集团是总部位于美国的金融控股公司，核心子公司为庞塞银行，主要服务纽约大都会区的多元文化、移民及中低收入社区，提供存款账户、按揭贷款、小微企业融资、个人信贷等零售及商业银行服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PDLB vs RGNX — 直观对比
营收规模更大
PDLB
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出5.4%
37.6%
净利率更高
PDLB
高出257.6%
-221.3%
自由现金流更多
PDLB
多$107.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
23.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.4M | $30.3M |
| 净利润 | $10.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 43.6% | -190.0% |
| 净利率 | 36.3% | -221.3% |
| 营收同比 | 37.6% | 43.0% |
| 净利润同比 | 245.6% | -31.2% |
| 每股收益（稀释后） | $0.43 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PDLBRGNX
| Q4 25 | $31.4M | $30.3M | ||
| Q3 25 | $26.7M | $29.7M | ||
| Q2 25 | $26.5M | $21.4M | ||
| Q1 25 | $24.6M | $89.0M | ||
| Q4 24 | $22.8M | $21.2M | ||
| Q3 24 | $20.2M | $24.2M | ||
| Q2 24 | $20.2M | $22.3M | ||
| Q1 24 | $20.5M | $15.6M |
净利润PDLBRGNX
| Q4 25 | $10.1M | $-67.1M | ||
| Q3 25 | $6.5M | $-61.9M | ||
| Q2 25 | $6.1M | $-70.9M | ||
| Q1 25 | $6.0M | $6.1M | ||
| Q4 24 | $2.9M | $-51.2M | ||
| Q3 24 | $2.4M | $-59.6M | ||
| Q2 24 | $3.2M | $-53.0M | ||
| Q1 24 | $2.4M | $-63.3M |
毛利率PDLBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PDLBRGNX
| Q4 25 | 43.6% | -190.0% | ||
| Q3 25 | 32.8% | -176.3% | ||
| Q2 25 | 30.2% | -296.3% | ||
| Q1 25 | 32.5% | 13.6% | ||
| Q4 24 | 19.6% | -242.1% | ||
| Q3 24 | 15.2% | -256.6% | ||
| Q2 24 | 21.8% | -251.3% | ||
| Q1 24 | 18.3% | -408.8% |
净利率PDLBRGNX
| Q4 25 | 36.3% | -221.3% | ||
| Q3 25 | 24.3% | -208.3% | ||
| Q2 25 | 23.0% | -331.8% | ||
| Q1 25 | 24.2% | 6.8% | ||
| Q4 24 | 14.1% | -241.3% | ||
| Q3 24 | 12.1% | -246.3% | ||
| Q2 24 | 15.8% | -237.7% | ||
| Q1 24 | 11.8% | -405.4% |
每股收益（稀释后）PDLBRGNX
| Q4 25 | $0.43 | $-1.30 | ||
| Q3 25 | $0.27 | $-1.20 | ||
| Q2 25 | $0.25 | $-1.38 | ||
| Q1 25 | $0.25 | $0.12 | ||
| Q4 24 | $0.11 | $-0.99 | ||
| Q3 24 | $0.10 | $-1.17 | ||
| Q2 24 | $0.14 | $-1.05 | ||
| Q1 24 | $0.11 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $126.2M | $230.1M |
| 总债务越低越好 | $596.1M | — |
| 股东权益账面价值 | $541.5M | $102.7M |
| 总资产 | $3.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 1.10× | — |
8季度趋势，按日历期对齐
现金及短期投资PDLBRGNX
| Q4 25 | $126.2M | $230.1M | ||
| Q3 25 | $146.6M | $274.2M | ||
| Q2 25 | $126.6M | $323.3M | ||
| Q1 25 | $129.9M | $267.9M | ||
| Q4 24 | $139.8M | $234.7M | ||
| Q3 24 | $155.8M | $255.5M | ||
| Q2 24 | $103.2M | $290.4M | ||
| Q1 24 | $134.7M | $338.7M |
总债务PDLBRGNX
| Q4 25 | $596.1M | — | ||
| Q3 25 | $521.1M | — | ||
| Q2 25 | $536.1M | — | ||
| Q1 25 | $521.1M | — | ||
| Q4 24 | $596.1M | — | ||
| Q3 24 | $580.4M | — | ||
| Q2 24 | $680.4M | — | ||
| Q1 24 | $680.4M | — |
股东权益PDLBRGNX
| Q4 25 | $541.5M | $102.7M | ||
| Q3 25 | $529.8M | $161.5M | ||
| Q2 25 | $521.1M | $213.7M | ||
| Q1 25 | $513.9M | $274.2M | ||
| Q4 24 | $505.5M | $259.7M | ||
| Q3 24 | $504.6M | $301.4M | ||
| Q2 24 | $497.7M | $348.3M | ||
| Q1 24 | $493.7M | $390.7M |
总资产PDLBRGNX
| Q4 25 | $3.2B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.2B | $581.0M | ||
| Q1 25 | $3.1B | $490.9M | ||
| Q4 24 | $3.0B | $466.0M | ||
| Q3 24 | $3.0B | $519.1M | ||
| Q2 24 | $2.8B | $569.4M | ||
| Q1 24 | $2.8B | $629.2M |
负债/权益比PDLBRGNX
| Q4 25 | 1.10× | — | ||
| Q3 25 | 0.98× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $55.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $54.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 173.9% | -174.0% |
| 资本支出强度资本支出/营收 | 3.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.48× | — |
| 过去12个月自由现金流最近4个季度 | $74.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PDLBRGNX
| Q4 25 | $55.6M | $-52.3M | ||
| Q3 25 | $1.4M | $-56.0M | ||
| Q2 25 | $6.2M | $-49.3M | ||
| Q1 25 | $13.1M | $33.6M | ||
| Q4 24 | $7.2M | $-31.6M | ||
| Q3 24 | $-14.6M | $-40.5M | ||
| Q2 24 | $-2.6M | $-45.5M | ||
| Q1 24 | $1.5M | $-55.5M |
自由现金流PDLBRGNX
| Q4 25 | $54.6M | $-52.8M | ||
| Q3 25 | $786.0K | $-56.5M | ||
| Q2 25 | $5.9M | $-49.7M | ||
| Q1 25 | $12.9M | $32.6M | ||
| Q4 24 | $4.5M | $-32.7M | ||
| Q3 24 | $-15.0M | $-40.9M | ||
| Q2 24 | $-2.6M | $-46.0M | ||
| Q1 24 | $-315.0K | $-56.0M |
自由现金流率PDLBRGNX
| Q4 25 | 173.9% | -174.0% | ||
| Q3 25 | 2.9% | -189.9% | ||
| Q2 25 | 22.4% | -232.8% | ||
| Q1 25 | 52.6% | 36.6% | ||
| Q4 24 | 19.7% | -154.2% | ||
| Q3 24 | -74.1% | -168.9% | ||
| Q2 24 | -13.0% | -206.2% | ||
| Q1 24 | -1.5% | -358.5% |
资本支出强度PDLBRGNX
| Q4 25 | 3.1% | 1.7% | ||
| Q3 25 | 2.3% | 1.7% | ||
| Q2 25 | 1.0% | 1.8% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 11.9% | 5.1% | ||
| Q3 24 | 2.0% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 8.7% | 3.6% |
现金转化率PDLBRGNX
| Q4 25 | 5.48× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 2.20× | 5.53× | ||
| Q4 24 | 2.46× | — | ||
| Q3 24 | -5.99× | — | ||
| Q2 24 | -0.80× | — | ||
| Q1 24 | 0.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PDLB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
